{"id":10997,"date":"2020-05-27T09:43:10","date_gmt":"2020-05-27T07:43:10","guid":{"rendered":"https:\/\/eestiarst.ee\/en\/?p=10997"},"modified":"2020-05-27T09:43:10","modified_gmt":"2020-05-27T07:43:10","slug":"an-update-of-the-current-diagnosis-and-treatment-of-adult-acute-myeloid-leukemia","status":"publish","type":"post","link":"https:\/\/eestiarst.ee\/en\/an-update-of-the-current-diagnosis-and-treatment-of-adult-acute-myeloid-leukemia\/","title":{"rendered":"An update of the current diagnosis and treatment of adult acute myeloid leukemia"},"content":{"rendered":"<p>Acute myeloid leukemia (AML) is a genetically, phenotypically, prognostically heterogeneous disease which has been treated with conventional chemotherapy and allogeneic stem cell transplantation until today. Recent advances in genomics and molecular biology have led to a greatly improved understanding of the pathophysiology, which enables a better classification, risk assessment and submicroscopic tracking of the disease. Following long term stagnation in the anti-leukemia drug development process, the clinical options are now changing fast with 8 new recently approved drugs. This includes therapies targeting molecular aberrations, anti-apoptotic pathways, surface antigens on leukemic cells and new pharmacokinetic compositions of classical cytostatic drugs. Integration of the new drugs into current treatment algorithms in order to offer a more personalized therapy will be a challenge. This approach hopefully enables to cure more AML patients, as well as to prolong their life expectancy and life quality. We are looking forward to see the upcoming discoveries.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Acute myeloid leukemia (AML) is a genetically, phenotypically, prognostically heterogeneous disease which has been treated with conventional chemotherapy and allogeneic stem cell transplantation until today. Recent advances in genomics and molecular biology have led to a greatly improved understanding of the pathophysiology, which enables a better classification, risk assessment and submicroscopic tracking of the disease. &#8230;<\/p>\n","protected":false},"author":5,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[2],"tags":[1538],"class_list":["post-10997","post","type-post","status-publish","format-standard","hentry","category-articles","tag-review"],"acf":[],"_links":{"self":[{"href":"https:\/\/eestiarst.ee\/en\/wp-json\/wp\/v2\/posts\/10997","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/eestiarst.ee\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/eestiarst.ee\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/eestiarst.ee\/en\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/eestiarst.ee\/en\/wp-json\/wp\/v2\/comments?post=10997"}],"version-history":[{"count":1,"href":"https:\/\/eestiarst.ee\/en\/wp-json\/wp\/v2\/posts\/10997\/revisions"}],"predecessor-version":[{"id":10998,"href":"https:\/\/eestiarst.ee\/en\/wp-json\/wp\/v2\/posts\/10997\/revisions\/10998"}],"wp:attachment":[{"href":"https:\/\/eestiarst.ee\/en\/wp-json\/wp\/v2\/media?parent=10997"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/eestiarst.ee\/en\/wp-json\/wp\/v2\/categories?post=10997"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/eestiarst.ee\/en\/wp-json\/wp\/v2\/tags?post=10997"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}